{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:55:30Z","timestamp":1770501330198,"version":"3.49.0"},"reference-count":29,"publisher":"Scientific Scholar","content-domain":{"domain":["surgicalneurologyint.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background:<\/jats:title>\n<jats:p>Postneurosurgical infection (PNSI) is a major problem. Linezolid is a bacteriostatic oxazolidinone antibiotic with a highly activity against Gram-positive cocci resistant to methicillin and a good cerebrospinal fluid penetration. The purpose of this study is to evaluate the efficacy of linezolid in the treatment of PNSI caused by methicillin-resistant <jats:italic>Staphylococcus<\/jats:italic> (MRS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Methods:<\/jats:title>\n<jats:p>We conducted an observational study for all patients over 14 years old and diagnosed with MRS PNSI. Demographic, clinical, and laboratory information were collected prospectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 10 patients with PNSI (6 meningitis, 2 ventriculitis, and 2 subdural empyema) received linezolid. MRS isolated was <jats:italic>Staphylococcus aureus<\/jats:italic> in seven cases and <jats:italic>Staphylococcus epidermidis<\/jats:italic> in three cases. All isolated microorganisms were susceptible to vancomycin (minimum inhibitory concentration (MIC) = 2 mg\/L) and linezolid (MIC = 1). The rate of microbiologic efficacy was 100% for patients with meningitis or ventriculitis. In the case of subdural empyema, focal infection had improved between 14 and 18 days. No adverse effects occurred during this study.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our results suggest that linezolid as an alternative to vancomycin for the treatment of PNSI caused by MRS with a high rate of efficacy.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/sni_455_2019","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:05:00Z","timestamp":1573225500000},"page":"215","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant <i>Staphylococcus<\/i>"],"prefix":"10.25259","volume":"10","author":[{"given":"Lotfi","family":"Rebai","sequence":"first","affiliation":[{"name":"Departments of Anesthesiology and Critical Care Medicine, Uninversity of Tunis El Manar, Tunisia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar","family":"Fitouhi","sequence":"additional","affiliation":[{"name":"Departments of Anesthesiology and Critical Care Medicine, Uninversity of Tunis El Manar, Tunisia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Aziz","family":"Daghmouri","sequence":"additional","affiliation":[{"name":"Departments of Anesthesiology and Critical Care Medicine, Uninversity of Tunis El Manar, Tunisia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Bahri","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery, Traumatology and Severe Burns Center, Faculty of Medicine of Tunis, Uninversity of Tunis El Manar, Tunisia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"10.25259\/SNI_455_2019\/ref-1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/ijmm.IJMM_17_41","article-title":"Methicillin-resistant Staphylococcus aureus intracranial abscess: An analytical series and review on molecular, surgical and medical aspects","volume":"36","author":"Bahubali","year":"2018","journal-title":"Indian J Med Microbiol"},{"key":"10.25259\/SNI_455_2019\/ref-2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMra0804573","article-title":"Nosocomial bacterial meningitis","volume":"362","author":"van de Beek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.25259\/SNI_455_2019\/ref-3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1468-1331.2008.02193.x","article-title":"EFNS guideline on the management of community-acquired bacterial meningitis: Report of an EFNS task force on acute bacterial meningitis in older children and adults","volume":"15","author":"Chaudhuri","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.25259\/SNI_455_2019\/ref-4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40262-013-0062-9","article-title":"Clinical pharmacokinetics of antibacterials in cerebrospinal fluid","volume":"52","author":"Di Paolo","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.25259\/SNI_455_2019\/ref-5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","article-title":"Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis","volume":"24","author":"Diaz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.25259\/SNI_455_2019\/ref-6","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/SNI_455_2019\/ref-7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0924-8579(15)30002-9","article-title":"Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: A 2014 follow-up survey","volume":"45","author":"Dryden","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.25259\/SNI_455_2019\/ref-8","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/jac\/dkg253","article-title":"Safety and tolerability of linezolid","volume":"51","author":"French","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.25259\/SNI_455_2019\/ref-9","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: Summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/SNI_455_2019\/ref-10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"10.25259\/SNI_455_2019\/ref-11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1684-1182(10)60073-4","article-title":"Clinical characteristics and risk factors for mortality in patients with meningitis caused by Staphylococcus aureus and vancomycin minimal inhibitory concentrations against these isolates","volume":"43","author":"Huang","year":"2010","journal-title":"J Microbiol Immunol Infect"},{"key":"10.25259\/SNI_455_2019\/ref-12","first-page":"177","article-title":"Management of shunt infections: A multicenter pilot study","volume":"105","author":"Kestle","year":"2006","journal-title":"J Neurosurg"},{"key":"10.25259\/SNI_455_2019\/ref-13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/02688697.2015.1006168","article-title":"Methicillin-resistant Staphylococcus aureus central nervous system infections analysis and outcome","volume":"29","author":"Kumari","year":"2015","journal-title":"Br J Neurosurg"},{"key":"10.25259\/SNI_455_2019\/ref-14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2014.07.001","article-title":"Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections","volume":"44","author":"Luque","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.25259\/SNI_455_2019\/ref-15","article-title":"M100-S24: Performance Standards for Antimicrobial Susceptibility Testing"},{"key":"10.25259\/SNI_455_2019\/ref-16","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00701-016-2915-0","article-title":"Sequential antimicrobial treatment with linezolid for neurosurgical infections: Efficacy, safety and cost study","volume":"158","author":"Mart\u00edn-Gandul","year":"2016","journal-title":"Acta Neurochir (Wien)"},{"key":"10.25259\/SNI_455_2019\/ref-17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s15010-007-7171-z","article-title":"Linezolid in postneurosurgical infections","volume":"36","author":"Maure","year":"2008","journal-title":"Infection"},{"key":"10.25259\/SNI_455_2019\/ref-18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1086\/518580","article-title":"Postoperative central nervous system infection: Incidence and associated factors in 2111 neurosurgical procedures","volume":"45","author":"McClelland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.25259\/SNI_455_2019\/ref-19","first-page":"Doc23","article-title":"Clinical characteristics of Staphylococcus epidermidis A systematic review","volume":"9","author":"Namvar","year":"2014","journal-title":"GMS Hyg Infect Control"},{"key":"10.25259\/SNI_455_2019\/ref-20","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.25259\/SNI_455_2019\/ref-21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1345\/aph.1H307","article-title":"Linezolid for the treatment of patients with central nervous system infection","volume":"41","author":"Ntziora","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.25259\/SNI_455_2019\/ref-22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2165\/00019053-200523090-00006","article-title":"Linezolid: A pharmacoeconomic review of its use in serious gram-positive infections","volume":"23","author":"Plosker","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.25259\/SNI_455_2019\/ref-23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhin.2018.02.011","article-title":"Nosocomial ventriculitis caused by a meticillin-and linezolid-resistant clone of Staphylococcus epidermidis in neurosurgical patients","volume":"100","author":"Rodr\u00edguez-Lucas","year":"2018","journal-title":"J Hosp Infect"},{"key":"10.25259\/SNI_455_2019\/ref-24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1468-1331.2005.01001.x","article-title":"Clinical experience with linezolid for the treatment of central nervous system infections","volume":"12","author":"Rupprecht","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.25259\/SNI_455_2019\/ref-25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.resmic.2011.12.004","article-title":"Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid","volume":"163","author":"Schwameis","year":"2012","journal-title":"Res Microbiol"},{"key":"10.25259\/SNI_455_2019\/ref-26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3109\/00365548.2011.585177","article-title":"Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: A series of 17 cases","volume":"43","author":"Sipahi","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.25259\/SNI_455_2019\/ref-27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/sur.2012.091","article-title":"Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis","volume":"14","author":"Sipahi","year":"2013","journal-title":"Surg Infect (Larchmt)"},{"key":"10.25259\/SNI_455_2019\/ref-28","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1128\/AAC.46.3.936-937.2002","article-title":"Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections","volume":"46","author":"Villani","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/SNI_455_2019\/ref-29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10096-013-2026-2","article-title":"Post-operative central nervous system infections after cranial surgery in China: Incidence, causative agents, and risk factors in 1,470 patients","volume":"33","author":"Zhan","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Surgical Neurology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/surgicalneurologyint.com\/linezolid-for-the-treatment-of-postneurosurgical-infection-caused-by-methicillin-resistant\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/linezolid-for-the-treatment-of-postneurosurgical-infection-caused-by-methicillin-resistant\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:05:07Z","timestamp":1573225507000},"score":1,"resource":{"primary":{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/linezolid-for-the-treatment-of-postneurosurgical-infection-caused-by-methicillin-resistant\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":29,"alternative-id":["10.25259\/SNI_455_2019"],"URL":"https:\/\/doi.org\/10.25259\/sni_455_2019","relation":{},"ISSN":["2152-7806"],"issn-type":[{"value":"2152-7806","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"article-number":"215"}}